Relationship of Clinical Symptoms and Substance Use in Schizophrenia Patients on Conventional Versus Atypical Antipsychotics

References

• Drake R E, Mueser K T, Clark R E, Wallach M A. The course, treatment, and outcome of substance disorder in persons with severe mental illnesses. Am J Orthopsychiatr 1996; 66: 42–51
   PubMed Web of Science ®Google Scholar
• Gupta S, Hendricks S, Kenkel A M, Bhatia S C, Haffke E A. Relapse in schizophrenia: is there a relationship to substance abuse?. Schizophr Res 1996; 20: 153–156
   PubMed Web of Science ®Google Scholar
• Soyka M. Dual diagnosis in patients with schizophrenia: issues in pharmacological treatment. CNS Drugs June, 1996; 5(6)414–425
   Google Scholar
• Tardiff K, Marzuk P M, Leon A C, Portera L, Weiner C. Violence by patients admitted to a private psychiatric hospital. Am J Psychiatry 1997; 154: 88–93
   PubMed Web of Science ®Google Scholar
• Heila H, Isometsa E T, Henriksson M M, Markus M, Heikkinen M E, Marttunen M J, Lonnqvist J K. Suicide and schizophrenia: a nationwide psychological autopsy study on age‐ and sex‐specific clinical characteristics of 92 suicide victims with schizophrenia. Am J Psychiatry 1997; 154: 1235–1242
   PubMed Web of Science ®Google Scholar
• Chambers R A, Krystal J H, Self D W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Soc Biol Psychiatry 2001; 50: 71–83
   PubMed Web of Science ®Google Scholar
• Keck P, Jr, Strakowski S M, McElroy S L. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility and suicidality in patients with schizophrenia. J Clin Psychiatry 2000; 61(Suppl. 3)4–9
   PubMedGoogle Scholar
• Scheller‐Gilkey G, Thomas S M, Woolwine B J, Miller A H. Increased early life stress and depressive symptoms in patients with comorbid substance abuse and schizophrenia. Schizophr Bull 2002; 2: 223–231
   Google Scholar
• Drake R E, Xie H, McHugo G J, Green A I. The effects of Clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000; 26(2)441–449
   PubMed Web of Science ®Google Scholar
• Littrell K H, Petty R G, Hilligoss N M, Peabody C D, Johnson C G. Olanzapine treatment for patients with schizophrenia and substance. J Subst Abuse Treat Dec 2001; 21(4)217–221
   PubMed Web of Science ®Google Scholar
• Green A I, Strous R D, Zimmet S V, Schildkraut J J. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward‐deficiency syndrome that can be ameliorated by clozapine?. Harv Rev Psychiatry 1999; 6: 287–296
   PubMed Web of Science ®Google Scholar
• Zimmet S V, Strous R D, Burgess E S, Kohnstamm S A, Green A I. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol 2000; 20(1)94–98
   PubMed Web of Science ®Google Scholar
• Buckley P F. New antipsychotic agents: emerging clinical profiles. J Clin Psychiatry 1999; 60(Suppl. 1)12–17
   PubMedGoogle Scholar
• Glick I D, Lemmens P, Vester‐Blokland E. Treatment of the symptoms of schizophrenia: a combined analysis of double‐blind studies comparing risperidone with haloperidol and other antipsychotic agents. Intl Clin Psychopharmacology 2001; 16(5)265–274
   PubMedGoogle Scholar
• McLellan A T, Kushner H, Metzger D, Peters R, Smith I, Grisson G, Pettinati H, Argeriou M. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9: 199–213
   PubMed Web of Science ®Google Scholar
• Rosenberg S D, Drake R E, Wolford G L. Dartmouth assessment of lifestyle instrument (DALI): a substance use disorder screen for people with severe mental illness. Am J Psychiatry 1998; 155(2)232–238
   PubMed Web of Science ®Google Scholar
• Kay S R, Fiszbein A, Opler L A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–276
   PubMed Web of Science ®Google Scholar
• Hamilton M A. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62
   PubMed Web of Science ®Google Scholar
• Davidson J RT, Book S W, Colkert J T, Tupler L A, Roth S, David D, Hertzberg M, Mellman T, Beckham J C, Smith R D, Davison R M, Katz R, Feldman M E. Assessment of a new self‐rating scale for posttraumatic stress disorder. Psychol Med 1997; 27: 153–160
   PubMed Web of Science ®Google Scholar
• Abnormal Involuntary Movement Scale (AIMS). NIMH Treatment Strategies in Schizophrenia Study. Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse an Mental Health Administration, National Institute of Mental Health, Rockville, MD 1985
   Google Scholar
• Simpson–Angus Neurobiological Rating Scale in NIMH Treatment Strategies in Schizophrenia Study. Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, National Institute of Mental Health, Rockville, MD 1986
   Google Scholar
• Awad A G. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993; 19(3)609–616
   PubMedGoogle Scholar
• Scheller‐Gilkey G, Moynes K, Robinson I, Kant C, Miller A. Early life stress and PTSD symptoms in patients with comorbid schizophrenia and substance abuse. Schizophr Res, (in press)
   Google Scholar
• Goldman R S, Tandon R, Liberzon I, Greden J F. Measurement of depression and negative symptoms in schizophrenia. Psychopathology 1992; 25: 49–56
   PubMed Web of Science ®Google Scholar
• Fenton W S, Blyler C R, Heinssen R K. Determinants of medication compliance schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23(4)637–651
   PubMed Web of Science ®Google Scholar
• Oehl M, Hummer M, Fleischhacker W W. Compliance with antipsychotic treatment. Acta Psychiatr Scand 2000; Suppl. 102(407)83–86
   Google Scholar